Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A activity. Read why I ...

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts ...

On Wednesday, Vertex Pharmaceuticals Incorporated (VRTX) stock saw a decline, ending the day at $470.05 which represents a decrease of $-4.86 or -1.02% from the prior close of $474.91. The stock ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Wells Fargo analyst Mohit Bansal has maintained their bullish stance on VRTX stock, giving a Buy rating yesterday. Mohit Bansal has given his ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $478.09, denoting a -1.02% change from the preceding trading day.

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.26% of ...

Another notable valuation metric for BMY is its P/B ratio of 6.19. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities.

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

New Century Financial Group LLC lessened its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 25.1% during the 3rd quarter, according to its most recent disclosure with ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 5 years by 6.32% on an annualized basis producing an ...